Abstract 465P
Background
This study evaluated the quality of oncological care of people with mental illness at an outer metropolitan centre.
Methods
A retrospective review of multidisciplinary team meetings (MDTs) was conducted and those with comorbid mental illness (“cases”) were identified. Demographic, psychiatric and oncological data were collected. Mental illness was stratified to 3 categories – Cat 1: mild affective disorders (uncomplicated depression/anxiety); Cat 2: complicated affective disorders (e.g. depression/anxiety with prior suicide attempt, hospitalisation and/or case management, substance use disorder and post-traumatic stress disorder); and Cat 3: severe mental illness (SMI) (e.g. bipolar affective disorder and schizophrenia). Patients without mental illness (“controls”) were randomly selected from the same tumour stream MDTs. Comparison between cases and controls was performed using Fisher’s exact test.
Results
Between 2021-2022, 853 patients were discussed at MDTs. 170 (20%) cases were identified, of whom 57%, 29% and 14% were in Cat 1, 2 and 3 respectively. Corresponding 170 controls were selected at random. Median age for cases was 65 vs. 71 for controls, p=0.03. No differences in sex and ethnicity were found. Cat 3 cases had the highest proportion receiving government financial aid (87%) vs. controls (57%) (Cat 1: 68%, Cat 2: 78%) p=0.001. Cat 3 cases also had the highest rates of ≥3 non-attendances to appointments (22%) vs. controls (7%) (Cat 1: 12%, Cat 2: 18%) p=0.006. Cases were found to have higher rates of metastatic disease at presentation (26% vs. 15% for controls, p=0.01). For patients offered active palliative treatment (n=80), cases had reduced adherence to the recommended treatment plan (70% vs. 91% for controls, p=0.03). Of those offered curative treatment (n=237), Cat 3 cases had the highest rates of cancer recurrence (33%) vs. controls (9%) (Cat 1: 12%, Cat 2: 18%) p=0.03.
Conclusions
Mental illness was associated with poorer cancer outcomes with increasing severity associated with even poorer outcomes, potentially reflecting higher rates of treatment non-adherence. This institutional study suggests that people with SMI have increased needs in navigating cancer care and highlights a need to examine this on a larger scale.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
Z.W. Wong: Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Other, Travel grant: Pfizer. Y. Antill: Financial Interests, Personal, Invited Speaker: GSK, MSD, AstraZeneca, Lilly, Eisai; Financial Interests, Institutional, Research Funding: AstraZeneca, MSD; Financial Interests, Personal, Advisory Board: GSK, MSD, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract